Trial Profile
Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONNECT
- Sponsors Biogen
- 17 Nov 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 28 Jul 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.